Literature DB >> 24141119

The thiol proteinase inhibitor E-64-d ameliorates amyloid-β-induced reduction of sAPPα secretion by reversing ceramide-induced protein kinase C down-regulation in SH-SY5Y neuroblastoma cells.

Fuminori Tanabe1, Tomoko Nakajima, Masahiko Ito.   

Abstract

In Alzheimer's disease (AD), enhancing α-secretase processing of amyloid precursor protein (APP) is an important pathway to decrease neurotoxic amyloid β (Aβ) secretion. The α-secretase is reported to be regulated by protein kinase C (PKC) and various endogenous proteins or cell surface receptors. In this report, we first examined whether Aβ reduces α-secretase activity, and showed that Aβ peptide 1-40 (0.001 and 0.01 μM) reduced the secretion of soluble amyloid precursor protein α (sAPPα) in carbachol-stimulated SH-SY5Y neuroblastoma cells. E-64-d (3 μM), which is a potent calpain inhibitor that prevents PKC degradation, ameliorated the Aβ-induced reduction of sAPPα secretion. In addition, we observed that Aβ significantly enhanced ceramide production by activating neutral sphingomyelinase. The cell-permeable ceramide analog, C2-ceramide (1 μg/mL), also reduced sAPPα secretion, and in addition, E-64-d eliminated the observed decrease of sAPPα secretion. C2-ceramide induced down-regulation of PKC-α, -β1, and -β2 isozymes in SH-SY5Y cells. These findings suggest that ceramide may play an important role in sAPPα processing by modulating PKC activity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid precursor protein; Calpain; Ceramide; Protein kinase C

Mesh:

Substances:

Year:  2013        PMID: 24141119     DOI: 10.1016/j.bbrc.2013.10.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Common mechanisms of Alzheimer's disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration.

Authors:  Brandon P Lucke-Wold; Ryan C Turner; Aric F Logsdon; James W Simpkins; Daniel L Alkon; Kelly E Smith; Yi-Wen Chen; Zhenjun Tan; Jason D Huber; Charles L Rosen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease.

Authors:  Priyanka Baloni; Matthias Arnold; Luna Buitrago; Kwangsik Nho; Herman Moreno; Kevin Huynh; Barbara Brauner; Gregory Louie; Alexandra Kueider-Paisley; Karsten Suhre; Andrew J Saykin; Kim Ekroos; Peter J Meikle; Leroy Hood; Nathan D Price; P Murali Doraiswamy; Cory C Funk; A Iván Hernández; Gabi Kastenmüller; Rebecca Baillie; Xianlin Han; Rima Kaddurah-Daouk
Journal:  Commun Biol       Date:  2022-10-08

3.  Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option.

Authors:  Diana Clausznitzer; Cesar Pichardo-Almarza; Ana Lucia Relo; Jeroen van Bergeijk; Elizabeth van der Kam; Loic Laplanche; Neil Benson; Marjoleen Nijsen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.